|
| | Dihydrostreptomycin Basic information |
| Product Name: | Dihydrostreptomycin | | Synonyms: | DIHYDROSTREPTOMYCIN;Dihydrostreptomycin (base and/or unspecified salts);2-[(1S,3R,4S,5R,6R)-5-(Diaminomethylideneamino)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-methylaminooxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine;Acetonitrile, 2-benzimidazolyl-;Benzimidazole, 2-cyanomethyl;4-O-[2-O-[2-(Methylamino)-2-deoxy-α-L-glucopyranosyl]-5-deoxy-3-hydroxymethyl-α-L-lyxofuranosyl]-N,N'-bis(aminoiminomethyl)-D-streptamine;DHSM;DihydroestreptoMycin Sulfate | | CAS: | 128-46-1 | | MF: | C21H41N7O12 | | MW: | 583.59 | | EINECS: | 204-888-2 | | Product Categories: | | | Mol File: | 128-46-1.mol |  |
| | Dihydrostreptomycin Chemical Properties |
| Melting point | >300 °C | | Boiling point | 641.09°C (rough estimate) | | density | 1.3963 (rough estimate) | | refractive index | 1.6800 (estimate) | | pka | pKa 7.8 (Uncertain) |
| Provider | Language |
|
2-[(1S,3R,4S,5R,6R)-5-(Diaminomethylideneamino)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-methylaminooxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine
| English |
| | Dihydrostreptomycin Usage And Synthesis |
| Originator | Dihydrostrepto,MSD ,US,1948 | | Uses | Antibacterial. | | Definition | ChEBI: Dihydrostreptomycin is a member of streptomycins. | | Manufacturing Process | Dihydrostreptomycin sulfate may be prepared from streptomycin sulfate by
catalytic hydrogenation (Merck, Pfizer, Cyanamid), electrolytic reduction
(Schenley, Olin Mathieson), or by sodium borohydride reduction (Bristol), or
by isolation from a fermentation process (Takeda). | | Brand name | Abocillin;Biostrep;Complexobiotico;Diapenin 3;Diapenin balsamico;Diarrestival;Didromycin;Didrothenate;Dihydrocidan sulfato;Dihydrostreptofar;Diidro-pantostrept;Distreptopab;Dreiciclina balsamica;Dst;Entera-strept;Estreptoluy;Estreptosirup;Helle-strep-forte;Hp 48;Mastigun;Mixtencillin;Retromyopen;Rocopenstrep;Sanstrepto;Solmycin;Solvo-strept;Streptoduocin;Veticar;Veycil-as. | | Therapeutic Function | Antibiotic | | World Health Organization (WHO) | Dihydrostreptomycin, a derivative of the aminoglycoside
antibiotic streptomycin with similar antibacterial activity, was first synthesized in
1947 and subsequently used in the treatment of tuberculosis and gram-negative
infections. Preparations for systemic use have been widely withdrawn as a result
of concern regarding their severe ototoxicity. Dihydrostreptomycin is poorly
absorbed from the gastrointestinal tract. It remains available in oral preparations in
some countries. | | Safety Profile | Poison by intravenous
and intramuscular routes. Moderately toxic
by subcutaneous and intraperitoneal routes.
Human teratogenic effects by unspecified
route: developmental abnormahties of the
eye and ear. An experimental teratogen.
Other experimental reproductive effects.
Mutation data reported. A derivative of
streptomycin; has anesthetic properties.
When heated to decomposition it emits
toxic fumes of NOx |
| | Dihydrostreptomycin Preparation Products And Raw materials |
|
